Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic β cells
Ting Yuan, Sahar Rafizadeh, Zahra Azizi, Blaz Lupse, Kanaka Durga Devi Gorrepati, Sushil Awal, Jose Oberholzer, Kathrin Maedler, Amin Ardestani
Ting Yuan, Sahar Rafizadeh, Zahra Azizi, Blaz Lupse, Kanaka Durga Devi Gorrepati, Sushil Awal, Jose Oberholzer, Kathrin Maedler, Amin Ardestani
View: Text | PDF
Research Article Cell biology Endocrinology

Proproliferative and antiapoptotic action of exogenously introduced YAP in pancreatic β cells

  • Text
  • PDF
Abstract

Loss of functional pancreatic β cells is a hallmark of both type 1 and 2 diabetes. Identifying the pathways that promote β cell proliferation and/or block β cell apoptosis is a potential strategy for diabetes therapy. The transcriptional coactivator Yes-associated protein (YAP), a major downstream effector of the Hippo signaling pathway, is a key regulator of organ size and tissue homeostasis by modulating cell proliferation and apoptosis. YAP is not expressed in mature primary human and mouse β cells. We aimed to identify whether reexpression of a constitutively active form of YAP promotes β cell proliferation/survival. Overexpression of YAP remarkably induced β cell proliferation in isolated human islets, while β cell function and functional identity genes were fully preserved. The transcription factor forkhead box M1 (FOXM1) was upregulated upon YAP overexpression and necessary for YAP-dependent β cell proliferation. YAP overexpression protected β cells from apoptosis triggered by multiple diabetic conditions. The small redox proteins thioredoxin-1 and thioredoxin-2 (Trx1/2) were upregulated by YAP; disruption of the Trx system revealed that Trx1/2 was required for the antiapoptotic action of YAP in insulin-producing β cells. Our data show the robust proproliferative and antiapoptotic function of YAP in pancreatic β cells. YAP reconstitution may represent a disease-modifying approach to restore a functional β cell mass in diabetes.

Authors

Ting Yuan, Sahar Rafizadeh, Zahra Azizi, Blaz Lupse, Kanaka Durga Devi Gorrepati, Sushil Awal, Jose Oberholzer, Kathrin Maedler, Amin Ardestani

×

Figure 4

YAP overexpression protects β cells from apoptosis.

Options: View larger image (or click on image) Download as PowerPoint
YAP overexpression protects β cells from apoptosis.
(A–F) INS-1E cells w...
(A–F) INS-1E cells were transfected with either control GFP or YAP plasmid and treated with (A and B) the proinflammatory cytokines recombinant human IL-1β (2 ng/ml) and 1,000 U/ml IFN-γ (IL/IF); or (C and D) 22.2 mM glucose (Glc) or the mixture of 22.2 mM glucose and 0.5 mM palmitate (22.2Palm) for 2 days; or (E and F) 25 μM H2O2 for 5 hours. Representative Western blots (A, C, and E) and quantitative densitometry analysis (B, D, and F) of cleaved caspase-3 (Cl Casp3) and cleaved PARP (Cl PARP) protein levels are shown. (B) Cl Casp3 (n = 5) and Cl PARP (n = 3). (D) Cl Casp3 (n = 4) and Cl PARP (n = 3). (F) Cl Casp3 (n = 3) and Cl PARP (n = 3). Data are the mean ± SEM. *P < 0.05 for treated GFP-transfected compared with untreated GFP-transfected condition. **P < 0.05 for treated YAP-transfected compared with treated GFP-transfected conditions. §P = 0.06 for 22.2 mM glucose–treated YAP-transfected compared with 22.2 mM glucose–treated GFP-transfected condition. §§P = 0.07 for 22.2Palm-treated YAP-transfected compared with 22.2Palm-treated GFP-transfected condition. All by 2-tailed Student’s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts